[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - OtherControl group: Conventional treatments used in ARDS", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - OtherIntervention group: Phase one: 12 patients with COVID-19 in two groups of 6 with ARDS (each group includes intervention groups of 3). Phase Two: 60 patients with COVID-19-ARDS in two groups of 30 controls and intervention. Classified A and B in both control and intervention groups - Exosome receiving group (intervention groups) \u2022 Injection material: Umbilical Cord Stem Cell-derived exosomes\u2022 Injection rate: 100 million exosomes per kilogram of body weight \u2022 Injection carrier: Saline \u2022 Injection site: Intravenous", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1334, "treatment_name": "Umbilical cord mesenchymal stem cells", "treatment_type": "Advanced therapy medicinal products (atmp)", "pharmacological_treatment": "Biological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]